News

U.S. tracking of HPV in cervical precancers confirms half due to 16/18


 

FROM AN ACIP MEETING

As ACIP members met, Sanofi Pasteur announced that its quadrivalent HPV vaccine, Gardasil, was one step closer to receiving European approval for a two-dose schedule (0, 6 months) in girls and boys aged 9-13 years.

Finally, ACIP’s members unanimously affirmed efforts to update its 2007 HPV vaccine statement. The new statement, which still needs to go through editing before a final vote, consolidates and clarifies existing recommendations and updates background and clinical trial data. It also adds a variety of new sections including postlicensure safety data, areas of ongoing research, and future priorities, including the 9-valent vaccine and reduced-dose schedules, she said.

Dr. Hariri and Dr. Markowitz reported having no financial disclosures. Dr. Luxembourg is an employee of Merck.

pwendling@frontlinemedcom.com

Pages

Recommended Reading

Sepsis less common, less deadly in pregnancy
MDedge ObGyn
Suppressing interpregnancy HIV prevents infant transmission
MDedge ObGyn
CDC sounds alarm on hospital antibiotic use
MDedge ObGyn
HIV-1 has gained virulence over the course of the epidemic
MDedge ObGyn
Risk of condomless sex low if HIV-positive partner is well controlled on ART
MDedge ObGyn
Early treatment appears to clear virus in second HIV-infected newborn
MDedge ObGyn
No VAERS safety signal with Tdap in pregnancy
MDedge ObGyn
Hospital physician orders increased postpartum Tdap vaccination rates
MDedge ObGyn
FDA panel unanimously backs cobas HPV test as primary screening tool
MDedge ObGyn
Woman-to-woman HIV transmission likely in Texas case
MDedge ObGyn

Related Articles